MatchTx is a new Big Data healthcare analytics software company with unique patented technology for cancer research and oncology clinical trials. The informatics solution enables matching patients to cancer drugs and clinical trials with novel methods to find best matches using genetic, clinical, and outcome data.
MatchTx is the first to market with a purpose built personalized medicine data solution that functions where there are more data points than subjects. Other predictive analytics methods for cancer often fail when there are very large numbers of clinical and genetic data points of unknown significance impacting drug response.
The technology has being licensed exclusively from partner The Ohio State University. MatchTx has closed its initial private investment round for exponential growth of this Central Ohio company to leverage its highly competitive non-dilutive $250,000 TVSF grant project from the State of Ohio and continued research and IP at Ohio State. MatchTx plans its strategic market relaunch in Q3 2025.